Clinical Study of Effectiveness Topiramate in Children with Intractable Epilepsy.
- Author:
Young Mi CHOI
1
;
Sa Jun CHUNG
Author Information
1. Department of Pediatrics, College of Medicine, Kyunghee University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Topiramate;
Partial seizure
- MeSH:
Anticonvulsants;
Asian Continental Ancestry Group;
Child*;
Epilepsy*;
Exanthema;
Humans;
Prospective Studies;
Seizures
- From:Journal of the Korean Pediatric Society
2001;44(1):62-67
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Topiramate(TPM) is a new anticonvulsant with multiple action mechanisms which should theoretically represent a wide therapeutic spectrum. However, there is still little clinical experience of its use in Asian children with epilepsy. METHODS: The patients were total 96 children who were treated with more than 2 anticonvulsants but poorly controlled seizure activity. TPM was given as add-on therapy and evaluated the efficacy and adverse events prospectively. This study consisted of 8 weeks of baseline phase, 10- 16 weeks titration phase, and 8 weeks of stabilization phase. Clinical efficacy was classified into 4 groups : disappearance, marked improvement, improvement, no improvement. RESULTS: When TPM was prescribed, a response of >50% reductions in seizure attacks was seen in 90.6% of cases(95.5% of partial type epilepsy) and disappearance was seen in 67.7% of cases (83.3% of generalized type epilepsy). Concommitent with the larger number of anticonvulsants a longer duration of epilepsy and more frequent seizure attack was showed more lower disappearance rate of seizure attack. Adverse event weight loss(9.4%), somnolence(7.3%), dizziness(5.2%), skin rash, decreased cognitive function, nocturia(3.1%) and headache(2.1%) were noted, but were mostly not serious. CONCLUSION: TPM seems to be a promising new broad-spectrum anticonvulsant, which is efficacious and safe in children with intractable epilepsy.
